ClinicalTrials.gg
TerminatedNCT01732913YosemiteUpdated Nov 16, 2018Results posted

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

A Phase 3 interventional study of Placebo and Rituximab in Indolent Non-Hodgkin's Lymphomas, sponsored by Gilead Sciences. Terminated at 103 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Enrollment
27th of 188
295 · median 48
Started
2013
with 6 others
Phase 3
35 of 194
2 open now
Registered
143rd of 194
by date

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 27th largest by enrollment of the 188 interventional ones that give a count, is one of 7 that started in 2013, is one of 35 in phase 3, and was the 143rd registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).

03

Conditions studied

  • Indolent Non-Hodgkin's Lymphomas

Keywords

  • iNHL
  • indolent NHL
  • follicular lymphoma
  • CAL-101
  • Rituximab
  • Small lymphocytic lymphoma
  • lymphoplasmacytoid lymphoma
  • Waldenstrom macroglobulinemia
  • LPL
  • WM
  • Marginal zone lymphoma
  • MZL
  • SLL
  • FL
  • GS-1101
  • idelalisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:

    1. Follicular lymphoma (FL) Grade 1, 2, or 3a
    2. Small lymphocytic lymphoma (SLL) with absolute lymphocyte count \< 5 x 10\^9/L at the time of diagnosis
    3. Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
    4. Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)

Key Exclusion Criteria:

  • History of lymphoid other than those allowed per inclusion criteria
  • Ongoing drug-induced liver injury, active , active , alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
  • Received previous treatment with rituximab that was not effective.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
295 participants (actual)

Study arms

  • Experimental
    Rituximab + idelalisib

    Participants will receive rituximab + idelalisib.

    Drug: Rituximab · Drug: Idelalisib

  • Placebo comparator
    Rituximab + Placebo

    Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.

    Drug: Placebo · Drug: Rituximab · Drug: Idelalisib

Interventions

  • DrugPlacebo

    Tablets administered orally twice daily

  • 375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)

    Also known as: Rituxan®, MabThera®

  • 150 mg tablets administered orally twice daily

    Also known as: GS-1101, CAL-101, Zydelig®

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Progression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphoma (iNHL) disease progression or death from any cause. PFS was to be assessed by an independent review committee (IRC).

Secondary outcomes

  1. Overall Response Rate

    Overall Response Rate (ORR) is defined as the proportion of participants who achieve a complete response or partial response (or very good partial response or minor response for participants with Waldenstrom's). ORR was to be assessed by an IRC.

  2. Lymph Node Response Rate

    Lymph node response rate is defined as the proportion of participants who achieve ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Lymph node response rate was to be assessed by an IRC.

  3. Complete Response Rate

    Complete response rate is defined as the proportion of participants who achieve a complete response. Complete response rate was to be assessed by an IRC.

  4. Overall Survival

    Overall survival is defined as the interval from randomization to death from any cause.

07

Results

Posted May 11, 2017
Limitations and caveats
Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.

Participant flow

Participants were enrolled at study sites in the North America, Europe, and Asia Pacific. The first participant was screened on 16 January 2013. The last study visit occurred on 18 May 2016.

Participant flow — Overall Study
MilestoneIdelalisib + RituximabPlacebo + Rituximab
Started19897
Completed4228
Not completed15669
Withdrew: Study terminated by sponsor10555
Withdrew: Withdrawal by subject274
Withdrew: Physician decision147
Withdrew: Other71
Withdrew: Initiation of other anti-cancer therapy32

Outcome measures

PrimaryProgression Free Survival

Progression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphoma (iNHL) disease progression or death from any cause. PFS was to be assessed by an independent review committee (IRC).

No measurements were reported for this outcome.

SecondaryOverall Response Rate

Overall Response Rate (ORR) is defined as the proportion of participants who achieve a complete response or partial response (or very good partial response or minor response for participants with Waldenstrom's). ORR was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryLymph Node Response Rate

Lymph node response rate is defined as the proportion of participants who achieve ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Lymph node response rate was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryComplete Response Rate

Complete response rate is defined as the proportion of participants who achieve a complete response. Complete response rate was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival is defined as the interval from randomization to death from any cause.

No measurements were reported for this outcome.

Adverse events

Collected over Up to 27 months plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib + Rituximab—103/198 (52%)189/198 (95.5%)
Placebo + Rituximab—11/95 (11.6%)83/95 (87.4%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventIdelalisib + RituximabPlacebo + Rituximab
PneumoniaInfections and infestations19/1980/95
DiarrhoeaGastrointestinal disorders18/1980/95
Alanine aminotransferase increasedInvestigations11/1980/95
Aspartate aminotransferase increasedInvestigations10/1980/95
PyrexiaGeneral disorders9/1981/95
ColitisGastrointestinal disorders8/1980/95
PneumonitisRespiratory, thoracic and mediastinal disorders8/1980/95
Febrile neutropeniaBlood and lymphatic system disorders7/1980/95
SepsisInfections and infestations5/1980/95
Acute kidney injuryRenal and urinary disorders5/1980/95
Most frequent other events
Showing 10 of 40
Most frequent other events
EventIdelalisib + RituximabPlacebo + Rituximab
DiarrhoeaGastrointestinal disorders88/19818/95
Alanine aminotransferase increasedInvestigations65/1980/95
Aspartate aminotransferase increasedInvestigations56/1980/95
NauseaGastrointestinal disorders50/19812/95
PyrexiaGeneral disorders50/19811/95
FatigueGeneral disorders41/19820/95
Infusion related reactionInjury, poisoning and procedural complications36/19820/95
RashSkin and subcutaneous tissue disorders38/19812/95
HeadacheNervous system disorders30/19812/95
CoughRespiratory, thoracic and mediastinal disorders28/19814/95

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set: all participants who were randomized regardless of whether they received any study treatment

Age, Continuous
Age, Continuous(years)Idelalisib + RituximabPlacebo + RituximabTotal
Mean64 ± 11.467 ± 11.465 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib + RituximabPlacebo + RituximabTotal
Female9948147
Male9949148
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + RituximabPlacebo + RituximabTotal
Asian351752
Black or African American549
White12354177
Other336
Not Permitted321951
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + RituximabPlacebo + RituximabTotal
Hispanic or Latino12315
Not Hispanic or Latino15075225
Unknown or Not Reported361955
Region of Enrollment
Region of Enrollment(Participants)Idelalisib + RituximabPlacebo + RituximabTotal
Russian Federation729
Singapore549
Romania101
Hungary24630
United States653499
Japan23932
United Kingdom314
Portugal314
Spain606
Czech Republic202
Sweden628
Taiwan112
Poland5712
Korea, Republic of426
Italy7411
Israel303
Australia7613
France251742
Germany112
08

Study locations

103 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Ironwood Cancer and Research Center
    Chandler, Arizona 85224, United States
  • City of Hope Cancer Center
    Duarte, California 91010, United States
  • Saint Jude Heritage Healthcare
    Fullerton, California 92835, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Cancer Care Associates
    Redondo Beach, California 90277, United States
  • Cancer Center of Santa Barbara
    Santa Barbara, California 93105, United States
  • Central Coast Medical Oncology Group
    Santa Maria, California 93454, United States
  • Middlesex Hospital Cancer Center
    Middletown, Connecticut 06457, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists and Research Institute
    Fort Myers, Florida 33916, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169-3321, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Prairie Lakes Healthcare System
    Watertown, South Dakota 57252, United States
  • Tennessee Oncology, PLLC
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Brooke Army Medical Center
    Fort Sam Houston, Texas 78234, United States
  • Center for Cancer and Blood Disorders, PC
    Fort Worth, Texas 76104, United States
  • Shenandoah Oncology Associates, PC
    Winchester, Virginia 22601, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Froedtert Hospital and Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Haematology and Oncology Clinics of Australia at Chermside
    Milton, Queensland 4064, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Saint Vincent's Hospital
    Fitzroy, Victoria 3065, Australia
  • Western Hospital
    Footscray, Victoria 3011, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Adelaide Cancer Centre
    Kurralta Park, SA 5037, Australia
  • Fiona Stanley Hospital
    Murdoch, 6150, Australia
  • Fakultní nemocnice Hradec Králové
    Hradec Králové, 500 05, Czechia
  • University Hospital of Bordeaux
    Pessac, Aquitaine 33604, France
  • Hôpital Necker-Enfants Malades
    Paris, Ile-de-france 75015, France
  • Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez
    Lille cedex, NORD Pas-de-calais 59037, France
  • Centre Hospitalier Universitaire Brest
    Brest, 29609, France
  • Centre Hospitalier de Dunkerque
    Dunkerque, 59385, France
  • Centre Hospitalier de Versailles
    Le Chesnay, 78157, France
  • Centre Léon Bérard
    Lyon Cedex 08, 69373, France
  • Hôpital Hôtel-Dieu
    Nantes cedex 1, 44093, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite Cedex, 69495, France
  • Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie
    Poitiers Cedex, 86000, France
  • Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
    Villingen-Schwenningen, Baden-wuerttemberg 78052, Germany
  • Gemeinschaftspraxis Dres. Söling Und Siehl
    Kassel, Hessen 34119, Germany
  • Debreceni Egyetem Orvos-és Egészségtudományi Centrum
    Debrecen, Hajdu-bihar 4032, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, Somogy 7400, Hungary
  • Markusovszky Egyetemi Oktatókórház
    Szombathely, VAS 9700, Hungary
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Országos Onkológiai Intézet
    Budapest, 1122, Hungary
  • Hadassah Medical Organization, Ein Kerem
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petach Tikva, 49100, Israel
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliero Universitaria (AOU) "Maggiore della Carita" di Novara
    Novara, 28100, Italy
  • Azienda Ospedaliera Ospedali Riuniti Marche Nord
    Pesaro, 61100, Italy
  • Centro di Riferimento Oncologico di Aviano
    Pordenone, 33081, Italy
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Nagoya City University Hospital
    Nagoya City, Aichi 467-8681, Japan
  • National Hospital Organization Nagoya Medical Center
    Nagoya-shi, Aichi 4600001, Japan
  • Aichi Cancer Center Hospital
    Nagoya, Aichi 464-8681, Japan
  • National Hospital Organization Kyushu Cancer Center
    Minami Ku, Fukuoka 811-1395, Japan
  • Kobe City Medical Center General Hospital
    Kobe-city, Hyogo 650-0047, Japan
  • Tokai University Hospital
    Isehara-shi, Kanagawa 259-1193, Japan
  • National Hospital Organization Kumamoto Medical Center
    Chuo-ku, Kumamoto 860-0008, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 9808574, Japan
  • Okayama University Hospital
    Okayama-city, Okayama 700-8558, Japan
  • Osaka City University Hospital
    Osaka-shi, Osaka 545-8586, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 1040045, Japan
  • The Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo 135-8550, Japan
  • Toranomon Hospital
    Minato-ku, Tokyo 1058470, Japan
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-876, Korea, Republic of
  • Malopolskie Centrum Medyczne S.C.
    Kraków, 30-510, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim
    Olsztyn, 10-228, Poland
  • Centrum Onkologii i Hipertermii
    Warszawa, 02-781, Poland
  • Hospital Geral de Santo António do Centro Hospitalar do Porto
    Porto, 4099-001, Portugal
  • Institutul Clinic Fundeni
    Bucuresti, 022328, Romania
  • Sverdlovsk Regional Clinical Hospital #1
    Ekaterinburg, 620102, Russian Federation
  • Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko
    Nizhniy Novgorod, 603126, Russian Federation
  • Ryazan Regional Clinical Hospital
    Ryazan, 390039, Russian Federation
  • FSI "V.A. Almazov Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies"
    Saint Petersburg, 197341, Russian Federation
  • Saint Petersburg I.P. Pavlov State Medical University
    Saint-Petersburg, 197022, Russian Federation
  • Saratov State Medical University
    Saratov, 410 028, Russian Federation
  • Singapore General Hospital
    Singapore, 169608, Singapore
  • National Cancer Centre Singapore
    Singapore, 169610, Singapore
  • Gleneagles Medical Centre
    Singapore, 258500, Singapore
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, 08916, Spain
  • Skånes Universitetssjukhus, Malmö
    Malmö, 205 02, Sweden
  • Chang Gung Memorial Hospital (CGMH)
    Kaohsiung, 83301, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan

Showing the first 100 of 103 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in May 2016, 40 months.

Results were first posted in May 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2012
First posted
Nov 26, 2012
StartActual
Jan 16, 2013
Primary completionActual
May 18, 2016
CompletionActual
May 18, 2016
Results first posted
May 11, 2017
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01732913
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 26, 2012
Start date
Jan 16, 2013
Primary completion
May 18, 2016
Completion
May 18, 2016
Results posted
May 11, 2017
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Idelalisib

Start the discussion